LUCIUS 卢修斯 阿法替尼 Afatinib非小细胞肺癌

阿法替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Afatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

非小细胞肺癌

Composition:
Each tilm-coated tablet contains Afatinib dimaleate

LUCÎUS

59.12 mg equivalent to Afatiaib .. 00m
Indication:

PHARMACEUTICALS

LuciAfa is akinase iniibifor indicated for
.First-line treatment of patients with metastatie
non-small cell lung cancer (NSCLC) whose tumors
Aave noa-resistant epidermal growth factor recepto
(EGFR) mutations as detected by an FDA approved

LuciAfa

Treatment of patients with metastitic, squamous
ASCLC progressing after plitinum-based

FDA批准

Derage and Vse:
*Recommended d

Afatinib Tablets

Kecommended dose: 40 mg orally, once daily
pairrment: 30 mz orally, once dailr
Palenits bitd sevete renal impairmnent
lastructpatients

40mg

mstruct patients to take LuciAfa at least I ho
before or 2 hours after a meal.
Storage: in a dru nlice and store at 20°C 1o 25 C.

30 Tablets

Kcep medicine out of reach of Children. Do not
administer LuciAfa ducin Preonancy and Lactation.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by

权威认证

LUCIUS
Thongmang village. Xaythany district.
Vientiane Capital, Laos
Warning: Tobe sold by retati on prescrpuon
nly and as cirecic

Rx only

口碑质量

适应症:
1、用于转移性非小细胞肺癌(NSCLC)患者的一线治疗,其肿瘤通
过FDA批准的测试方法检测为非耐药性表皮生长因子受体

(EGFR)突变。
2、用于铂类化疗后进展的转移性鳞状非小细胞肺癌患者的治疗。
推荐剂量:

1、每日口服一次,每次40mg。
2、严重肾功能损伤患者,每日口服一次,每次30mg。
3、空腹服用(饭前1小时或饭后2小时服用)。